Frontiers

UpfrontSu13

​ Helping Ourselves One of the most exciting projects recently launched and led by Ohio State’s cancer program is a statewide initiative to screen newly diagnosed colorectal cancer (CRC). MICHAEL A. CALIG ...[Read more]
Published: Jul-30-13 | 4  Comments | 0  Link to this post

Frontline Summer 2013

​A Game-Changer The Personal Cancer Genome and Precision Cancer Trials By SAMEEK ROYCHOWDHURY, MD, PhD, assistant professor of Internal Medicine and of PharmacologyClinical trials traditionally have been designed to treat patients with a ...[Read more]
Published: Jul-30-13 | 4  Comments | 0  Link to this post

Breakthrough Summer 2013

​ CLINICAL IMPLICATIONS New Agent May Control Breast Cancer Growth and Spread CARLO CROCE, MD, professor and chair, Molecular Virology, Immunology and Medical Genetics; director, Human Cancer Genetics and the John ...[Read more]
Published: Jul-30-13 | 3  Comments | 0  Link to this post

Of Note Summer 2013

​ GRANTS MICHAEL A. CALIGIURI, MD, director of the OSUCCC and CEO of The James, and E. Antonio Chiocca, MD, PhD,  of Brigham and Women’s Hospital in Boston, have received a five-year National Cancer Institu ...[Read more]
Published: Jul-30-13 | 3  Comments | 0  Link to this post

The Most Deadly Skin Cancer

​ THE MOST DEADLY SKIN CANCER Clinical and translational research at Ohio State and elsewhere are improving care for people with melanoma, one of the few cancers that is increasing in incidence BY BOB HECKER ARTWORK ...[Read more]
Published: Jul-30-13 | 4  Comments | 0  Link to this post

Going Statewide

​ GOING STATEWIDE A cancer research and prevention effort supported by Pelotonia is designed to reduce morbidity and mortality from colorectal cancer in Ohio By KENDALL POWELL For the past two years in August, Jenny and E ...[Read more]
Published: Jul-30-13 | 4  Comments | 0  Link to this post

Synergistic Science

​ ​ SYNERGISTIC SCIENCE Original research at the OSUCCC–James leads to innovative clinical trials such as OSU-10080 BY DARRELL E. WARD Women diagnosed with triple-negative breast cancer face significant challenges.Tri ...[Read more]
Published: Jul-30-13 | 3  Comments | 0  Link to this post

From Bench to Bedside 2013

​OSU-11055:  Model development to personalize dosing for intravenous melphalan in the setting of autologous transplant for multiple myelomaOSU-11055:  Model development to personalize dosing for intravenous melphalan in the setting of autologous tra ...[Read more]
Published: Jul-30-13 | 4  Comments | 0  Link to this post

 Next >>